Search companies

Live

Tuesday, 17 November 2026 · 581 Summaries Today

S&P/ASX 200 · 8,883.20 (-1.79%)

Dimerix Cash More Than Doubles as Licensing Payment and Funding Facility Bolster Trial Runway

Dimerix Limited (DXB) · Health care

DXB: $0.215 +4.88% · MC: $120M

Dimerix's cash rose to approximately $35 million at the end of September from $16 million three months earlier, after it received an approximately $14 million upfront licensing payment and drew $17 million from a $34 million funding facility. The company says it has sufficient funding to complete the pivotal ACTION3 trial of DMX-200 and continue advancing the Phase 2 trial of newly acquired kidney injury treatment DMX-652. The first patients have completed the ACTION3 treatment period and moved into follow-up, while Hugh Alsop has been appointed interim chair following Mark Diamond's retirement.

Source announcements: 2026-10-29 08:31 to 2026-10-29 08:31 Sydney time
Story updated 2026-10-29 11:36 Sydney time
SourcesDimerix Quarterly Activities Report and Appendix 4C
Comments